Muhammad M Qureshi1, Paul B Romesser1, Abdallah Ajani1, Lisa A Kachnic1, Scharukh Jalisi2, Minh Tam Truong1. 1. Department of Radiation Oncology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts. 2. Department of Otolaryngology, Division of Head and Neck Surgical Oncology and Skull Base Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts.
Abstract
BACKGROUND: The purpose of this study was to evaluate how gross tumor volume (GTV) affects treatment outcome among different race/ethnic groups in patients with head and neck cancer receiving definitive radiotherapy (RT). METHODS: Ninety-one patients with head and neck cancer were treated to a median RT dose of 69.96 Gy in 33 fractions. The patient's self-reported race/ethnicity, primary tumor, and nodal GTV were obtained. Two-year actuarial local, nodal, and distant control, and overall and disease-free survival were calculated. RESULTS: The patients were categorized as white (n = 43) or non-white (n = 48), which included 29 African Americans, 11 Hispanics, 5 Asians, and 3 others. The mean primary GTV was 21.0 cc and 39.9 cc for whites and non-whites, respectively (p = .011). White patients reported improved overall survival of 85.4% compared to non-whites (65.8%; p = .006). Improvements in local and nodal control and disease-free survival rates were also observed. CONCLUSION: White patients demonstrated improved treatment outcomes compared with non-whites, which may be reflective of tumor volume.
BACKGROUND: The purpose of this study was to evaluate how gross tumor volume (GTV) affects treatment outcome among different race/ethnic groups in patients with head and neck cancer receiving definitive radiotherapy (RT). METHODS: Ninety-one patients with head and neck cancer were treated to a median RT dose of 69.96 Gy in 33 fractions. The patient's self-reported race/ethnicity, primary tumor, and nodal GTV were obtained. Two-year actuarial local, nodal, and distant control, and overall and disease-free survival were calculated. RESULTS: The patients were categorized as white (n = 43) or non-white (n = 48), which included 29 African Americans, 11 Hispanics, 5 Asians, and 3 others. The mean primary GTV was 21.0 cc and 39.9 cc for whites and non-whites, respectively (p = .011). Whitepatients reported improved overall survival of 85.4% compared to non-whites (65.8%; p = .006). Improvements in local and nodal control and disease-free survival rates were also observed. CONCLUSION:Whitepatients demonstrated improved treatment outcomes compared with non-whites, which may be reflective of tumor volume.
Authors: Gordon O Schoenfeld; Robert J Amdur; Christopher G Morris; Jonathan G Li; Russell W Hinerman; William M Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 2007-12-31 Impact factor: 7.038
Authors: Kathleen Settle; Marshall R Posner; Lisa M Schumaker; Ming Tan; Mohan Suntharalingam; Olga Goloubeva; Scott E Strome; Robert I Haddad; Shital S Patel; Earl V Cambell; Nicholas Sarlis; Jochen Lorch; Kevin J Cullen Journal: Cancer Prev Res (Phila) Date: 2009-07-29
Authors: Paul B Romesser; Muhammad M Qureshi; Bhartesh A Shah; Luke T Chatburn; Scharukh Jalisi; Anand K Devaiah; Rathan M Subramaniam; Minh Tam Truong Journal: Ann Nucl Med Date: 2012-05-19 Impact factor: 2.668